F m Investments LLC Boosts Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

F m Investments LLC boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 21.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,803 shares of the specialty pharmaceutical company’s stock after purchasing an additional 11,753 shares during the period. F m Investments LLC owned about 0.30% of ANI Pharmaceuticals worth $5,352,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ANIP. Arrowstreet Capital Limited Partnership bought a new stake in ANI Pharmaceuticals during the 3rd quarter valued at $32,992,000. Balyasny Asset Management L.P. raised its holdings in ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after acquiring an additional 276,233 shares during the period. Divisadero Street Capital Management LP bought a new stake in ANI Pharmaceuticals during the 3rd quarter valued at $21,454,000. Rubric Capital Management LP raised its holdings in ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after acquiring an additional 200,998 shares during the period. Finally, UBS Group AG raised its holdings in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after acquiring an additional 185,172 shares during the period. Institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Ori Gutwerg sold 2,060 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total value of $157,590.00. Following the transaction, the senior vice president owned 84,782 shares of the company’s stock, valued at approximately $6,485,823. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Stephen P. Carey sold 7,312 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $75.50, for a total transaction of $552,056.00. Following the completion of the transaction, the chief financial officer directly owned 185,543 shares in the company, valued at approximately $14,008,496.50. The trade was a 3.79% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 27,860 shares of company stock valued at $2,111,581. Corporate insiders own 8.10% of the company’s stock.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat Wall Street expectations on both earnings and revenue, reporting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. The company also said quarterly revenue rose 20.5% year over year, signaling solid underlying growth. Article Title
• Positive Sentiment: The company raised its FY 2026 EPS guidance to $9.19-$9.69, above the consensus estimate of $8.79, which suggests management sees stronger profitability ahead. Article Title
• Neutral Sentiment: Investors are also parsing the earnings call transcript and presentation for details on the company’s growth drivers and updated strategy, but the main stock catalyst today is the beat-and-raise quarter. Article Title
• Neutral Sentiment: ANI also issued revenue guidance around $1.1 billion for FY 2026, roughly in line with expectations, so the revenue outlook appears stable rather than a fresh upside surprise. Article Title

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th. Finally, Guggenheim boosted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Trading Down 2.4%

ANI Pharmaceuticals stock opened at $81.86 on Friday. The stock has a market cap of $1.83 billion, a P/E ratio of 24.36 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a fifty-two week low of $56.71 and a fifty-two week high of $99.50. The firm’s fifty day moving average price is $76.82 and its 200-day moving average price is $81.01. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.19 and a current ratio of 2.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 8.87% and a return on equity of 27.97%. The business’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.64 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.